Prostate Cancer Early Detection in the European Union and UK – APCCC
Advanced Prostate Cancer Consensus Conference shared on LinkedIn:
“Prostate Cancer Early Detection in the European Union and UK out on European Urology
Authors: Renée C.A. Leenen, Lionne D.F. Venderbos, Jozien Helleman, Juan Gómez Rivas, Pieter Vynckier, Lieven Annemans, Renata Chloupková, Ondřej Májek , Erik Briers, Vera Vasilyeva, Sebastiaan Remmers, Meike J. van Harten, Frederique B. Denijs, Ivo I. de Vos, Arunah Chandran, Partha Basu, Roderick C.N. van den Bergh, Sarah Collen, Hein Van Poppel, Monique J. Roobol, Katharina Beyer.
Comprehensive systematic review analyzes 26 existing reviews on Prostate Cancer (PCa) early detection in the EU and UK covering key themes such as invitation, decision-making, screening tests, harms, and benefits.
It highlights that while men over 50 should be invited for screening and population-wide screening is discouraged, shared decision-making (SDM) is inconsistently implemented.
- Prostate-specific antigen (PSA)-based screening can reduce PCa-specific mortality but comes with risks of overdiagnosis and overtreatment.
- Emerging tools like risk calculators and biomarkers show promise for future screening improvements.
The review underscores both established evidence and areas needing further research to optimize PCa screening strategies.”
Source: Advanced Prostate Cancer Consensus Conference/LinkedIn